TAYSHA GENE THERAPIES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.25 USD | +0.31% |
|
+12.46% | +83.62% |
| May. 14 | Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours | MT |
| May. 14 | Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,002 | 448.2 | 141.1 | 330.9 | 605.9 | - | - |
| Enterprise Value (EV) 1 | 750.9 | 299.1 | 91.21 | 227.5 | 543.2 | 459.2 | 272.1 |
| P/E ratio | -7.81 x | -2.51 x | -0.6 x | -1.84 x | -7.7 x | -6.51 x | -7.86 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 56.4 x | 21.4 x | 51.8 x | 102 x | 13.8 x |
| EV / Revenue | - | - | 36.5 x | 14.7 x | 46.4 x | 77.5 x | 6.21 x |
| EV / EBITDA | -17.5 x | -1.73 x | -0.73 x | -3.2 x | -6.8 x | -5.25 x | 7.87 x |
| EV / FCF | -24.4 x | -2.26 x | -0.84 x | -2.96 x | -5.17 x | -4.3 x | -4.32 x |
| FCF Yield | -4.1% | -44.2% | -120% | -33.8% | -19.3% | -23.3% | -23.2% |
| Price to Book | 3.99 x | 4.7 x | 105 x | 4.42 x | -64.8 x | -64.8 x | - |
| Nbr of stocks (in thousands) | 37,761 | 38,474 | 62,442 | 186,960 | 187,018 | - | - |
| Reference price 2 | 26.54 | 11.65 | 2.260 | 1.770 | 3.240 | 3.240 | 3.240 |
| Announcement Date | 3/3/21 | 3/31/22 | 3/28/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 2.502 | 15.45 | 11.7 | 5.922 | 43.82 |
| EBITDA 1 | -42.99 | -172.8 | -124.9 | -71.07 | -79.83 | -87.55 | 34.56 |
| EBIT 1 | -43 | -173.3 | -162.4 | -72.44 | -91.51 | -97.75 | -91.04 |
| Operating Margin | - | - | -6,492.69% | -468.83% | -782.09% | -1,650.59% | -207.74% |
| Earnings before Tax (EBT) 1 | -60.01 | -174.5 | -166 | -111.6 | -90.59 | -101.9 | -89.43 |
| Net income 1 | -60.01 | -174.5 | -166 | -111.6 | -90.59 | -101.9 | -84.55 |
| Net margin | - | - | -6,635.25% | -722.06% | -774.16% | -1,720.36% | -192.94% |
| EPS 2 | -3.400 | -4.640 | -3.780 | -0.9600 | -0.4210 | -0.4978 | -0.4120 |
| Free Cash Flow 1 | -30.81 | -132.3 | -109 | -76.89 | -105 | -106.9 | -63.02 |
| FCF margin | - | - | -4,356.87% | -497.62% | -897.53% | -1,804.57% | -143.8% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/3/21 | 3/31/22 | 3/28/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 2.502 | 4.706 | 2.395 | 4.746 | 3.604 | 3.411 | 2.424 | 2.439 | 2.521 | 2.035 | 2.442 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -49.72 | -49.27 | -32.98 | -25.07 | -55.12 | -16.56 | -23.38 | -15.63 | -16.25 | -24.33 | -21.9 | -22.28 | -22.18 | -25.15 | -25.8 |
| Operating Margin | - | - | - | - | -2,203.04% | -351.87% | -976.37% | -329.41% | -450.78% | -713.28% | -903.24% | -913.53% | -879.87% | -1,235.65% | -1,056.52% |
| Earnings before Tax (EBT) 1 | -50.39 | -50.11 | -33.87 | -26.31 | -55.72 | -17.62 | -24.6 | -117.1 | 47.74 | -24.06 | -22.37 | -22.58 | -22.69 | -25.68 | -26 |
| Net income 1 | -50.39 | -50.11 | -33.87 | -26.31 | -55.72 | -17.62 | -24.6 | -117.1 | 47.74 | -24.06 | -22.37 | -22.58 | -22.69 | -25.68 | -26 |
| Net margin | - | - | - | - | -2,227.14% | -374.46% | -1,027.06% | -2,467.07% | 1,324.67% | -705.39% | -922.88% | -925.95% | -900.08% | -1,261.58% | -1,064.64% |
| EPS 2 | -1.320 | -1.310 | -0.8400 | -0.6400 | -0.9900 | -0.2800 | -0.3800 | -0.9300 | 0.9200 | -0.1000 | -0.1060 | -0.1060 | -0.1040 | -0.1229 | -0.1200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/22 | 5/16/22 | 8/11/22 | 11/8/22 | 3/28/23 | 5/11/23 | 8/14/23 | 11/14/23 | 3/19/24 | 5/14/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 251 | 149 | 49.9 | 103 | 62.7 | 147 | 334 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -30.8 | -132 | -109 | -76.9 | -105 | -107 | -63 |
| ROE (net income / shareholders' equity) | -47.8% | -101% | -345% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 6.650 | 2.480 | 0.0200 | 0.4000 | -0.0500 | -0.0500 | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | 0.08 | 15.3 | 20.6 | 3.87 | 4.52 | 3.93 | 5.23 |
| Capex / Sales | - | - | 824.1% | 25.04% | 38.65% | 66.29% | 11.92% |
| Announcement Date | 3/3/21 | 3/31/22 | 3/28/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.24
USD
Average target price
6.95
USD
Spread / Average Target
+114.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +78.25% | 606M | |
| +50.97% | 63.85B | |
| -2.41% | 41.83B | |
| +40.01% | 40.47B | |
| -10.22% | 27.17B | |
| +13.48% | 26.52B | |
| -20.65% | 18.69B | |
| +2.81% | 12.73B | |
| +22.22% | 12.11B | |
| +27.76% | 12.07B |
- Stock Market
- Equities
- TSHA Stock
- Financials Taysha Gene Therapies, Inc.
